Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Wednesday, December 12, 2018 · 470,944,018 Articles · 3+ Million Readers

Cyclin Dependent Kinase 6 Market by Complete Overview for Therapeutics Development and Assessment, 2018

Cyclin Dependent Kinase 6

PUNE, MAHARASHTRA, INDIA, March 5, 2018 / -- with their unique quality of simplifying the market research study, presents a deep diving study report “Cyclin Dependent Kinase 6 - Pipeline Review, H1 2018”

Cyclin Dependent Kinase 6


Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC - Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation.

It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation-activity.

Click here for sample report @


Major Key Players:

Beta Pharma Inc

Eli Lilly and Co

G1 Therapeutics Inc

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Cyclin Dependent Kinase 6 Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Cyclin Dependent Kinase 6    - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cyclin Dependent Kinase 6   , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 2, 1, 8 and 1 respectively.   

Cyclin Dependent Kinase 6 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Cyclin Dependent Kinase 6 - Competitive Analysis

Key players are making innovative developments in Cyclin Dependent Kinase 6 industry.  The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector


The pipeline guide provides a snapshot of the global therapeutic landscape of Cyclin Dependent Kinase 6.

The pipeline guide reviews pipeline therapeutics for Cyclin Dependent Kinase 6 by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cyclin Dependent Kinase 6 therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cyclin Dependent Kinase 6 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 

The pipeline guide reviews latest news related to pipeline therapeutics for Cyclin Dependent Kinase 6.


For Detailed Reading Please visit @

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release